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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.024During tuberculosis (TB), some Mycobacterium tuberculosis bacilli persist in the presence of an active
immunity and antibiotics that are used to treat the disease. Herein, by using the Cornell model of TB
persistence, we further explored our recent ﬁnding that suggested thatM. tuberculosis can escape therapy
by residing in the bone marrow (BM) mesenchymal stem cells. We initially showed that M. tuberculosis
rapidly disseminates to the mouse BM after aerosol exposure and maintained a stable burden for at least
220 days. In contrast, in the lungs, the M. tuberculosis burden peaked at 28 days and subsequently
declined approximately 10-fold. More important, treatment of the mice with the antibiotics rifampicin
and isoniazid, as expected, resulted in effective clearance of M. tuberculosis from the lungs and spleen. In
contrast, M. tuberculosis persisted, albeit at low numbers, in the BM of antibiotic-treated mice. Moreover,
most viableM. tuberculosis was recovered from the bone marrow CD271þCD45-enriched cell fraction, and
only few viable bacteria could be isolated from the CD271CD45þ cell fraction. These results clearly show
that BM mesenchymal stem cells provide an antibiotic-protective niche for M. tuberculosis and suggest
that unraveling the mechanisms underlying this phenomenon will enhance our understanding of
M. tuberculosis persistence in treated TB patients. (Am J Pathol 2014, 184: 3170e3175; http://
dx.doi.org/10.1016/j.ajpath.2014.08.024)Supported by NIH grants R01AI076425 (A.C.-N.) and R56 AI111823
(A.C.-N. and G.B.), The Cummings School of Veterinary Medicine (Tufts
University), and by the KaviKrishna Foundation (Sualkuchi, Assam, India).
Disclosures: None declared.Mycobacterium tuberculosis, the causative agent of tuber-
culosis (TB), is an intracellular pathogen known to infect
primarily macrophages and dendritic cells.1e3 However, the
viability of M. tuberculosis in these intracellular niches is
poor,4 and no evidence exists indicating that these cells can
maintain live nonreplicating M. tuberculosis for long pe-
riods of time. Therefore, it is unlikely that these cell pop-
ulations can harbor viable M. tuberculosis during the
chronic phase of the disease, which lasts for months or
years, as well as during the latent TB infection, which can
last for decades.
We have recently shown that M. tuberculosis can reside
in bone marrow (BM) within the CD271þCD45 mesen-
chymal stem cells (BM-MSCs) of individuals treated for
pulmonary TB and in mice experimentally infected withstigative Pathology.
.M. tuberculosis.5 MSCs can provide an ideal protective niche
for M. tuberculosis because these cells have several proper-
ties that may promote the pathogen’s long-term persistence
and survival: i) MSCs are present in TB granulomas of
infected mouse and human lung tissue6; ii) stem cells possess
the capacity for self-renewal7; iii) stem cells express drug
efﬂux pumps, such as ABCG2, that could contribute to drug
evasion by M. tuberculosis5; iv) stem cells have low pro-
duction of reactive oxygen species,8 which may favor the
viability of nonreplicating M. tuberculosis; v) although
BM-MSCs Protect M.tb from AntibioticsMSCs have the capacity of self-renewal, they are relatively
quiescent,9 and reside in the immune-privileged niche of the
BM10,11; and vi) MSCs do not normally express major his-
tocompatibility complex (MHC) class II on their cell surface
and their MHC class I molecules are not functionally active
(ie, these molecules do not trigger effector functions of
cytotoxic T lymphocytes).12 Therefore, it is logical that BM-
MSCs constitute a host cell capable of supporting long-term
persistence of viable nonreplicating M. tuberculosis. How-
ever, many fundamental questions regarding the survival of
virulent M. tuberculosis in BM-MSCs remain unanswered.
Herein, we conﬁrmed in vivo in the mouse model of TB that
virulent M. tuberculosis disseminates rapidly to the BM
within 2 weeks after infection with aerosolized organisms
and preferentially resides within BM-MSCs. In addition, and
more important, we show that antibiotics appeared to efﬁ-
ciently clear the infectious process within the lungs and
spleens but fail to do so in the BM.
Materials and Methods
Six- to eight-week-old C57BL/6 female mice (Charles River
Laboratories, Kingston, NY) were exposed (nasally only) to
virulent M. tuberculosis Erdman strain using a CH Tech-
nologies (Westwood, NJ) aerosol-generating machine con-
tained within a class III biosafety cabinet in the New
England Regional Biosafety Laboratory (Grafton, MA). The
low-dose exposure deposited approximately 80 bacilli in the
lungs. After 28 days of infection, half of the mice received
100 mg/L rifampicin (RIF) with 250 mg/L isoniazid (INH)
in the drinking water, and the other half received sterile
acidiﬁed water. At the time points indicated, mice were
euthanized by CO2, and lungs, spleens, and BM were har-
vested, homogenized in sterile phosphate-buffered saline
(PBS), and plated onto oleate-albumin-dextrose-cata-
laseesupplemented 7H11 agar. BM was harvested from
both femurs and tibia from each mouse by ﬂushing with
sterile PBS, homogenized by pressing through 70-mm nylon
mesh screens to yield single-cell suspensions, and resus-
pended in 2 mL of PBS. In initial experiments, the entire 2
mL of BM from each mouse was plated onto agar for
colony-forming unit (CFU) recovery. In subsequent exper-
iments, 500 mL of the 2-mL BM from each mouse was
plated onto agar. The remaining 1.5 mL from four to six
mice was pooled, and red blood cells were lysed, counted
(yielding a calculated average of approximately
3.5  107cells per mouse), and enriched for BM-MSCs. The
enriched/depleted/unfractioned cells were plated onto agar
in duplicate or triplicate at the maximum number possible
for BM-MSCs or 1 to 1.25  107 cells for the depleted and
unfractioned cells. In some experiments, single-cell sus-
pensions were obtained from the BM, and enriched for
CD271þCD45 BM-MSCs using Stemcell Technologies
(Vancouver, BC, Canada) EasySep Mouse Mesenchymal
Stem/Progenitor Cell Enrichment Kit (catalog number
19771) for mouse MSCs, and fractions plated onto agar.The American Journal of Pathology - ajp.amjpathol.orgLung and spleen homogenates were serially diluted in sterile
PBS before plating. M. tuberculosis CFUs were counted
after at least 3 weeks at 37C. To conﬁrm the quality control
of the kit before using it inside the biosafety level 3 facility,
BM fractions were obtained from noninfected mice (outside
the biosafety level 3 facility) by ﬂushing the marrow out of
femur and tibia, followed by softening of bone chips by
incubation in solution containing 0.25% collagenase type I
in PBS þ 20% fetal bovine serum for 45 minutes at 37C.
The mononuclear cells were then ﬁltered through a 70-mm
cell strainer and washed twice in PBS containing 2% fetal
bovine serum. The CD45 fractions were obtained by per-
forming magnetic sorting, and the isolated cell population
was stained for anti-CD45 (17-0451-83, activated protein C
labeled; eBiosciences, San Diego, CA), anti-CD271
(ab62122, ﬂuorescein isothiocyanate labeled; Abcam,
Cambridge, MA), or isotype-matched controls. Flow
cytometry analysis was performed on an AccuriC6 cytom-
eter (BD Biosciences, San Jose, CA). We were able to
collect a calculated average of 2.8  106 of CD45 cells
from 3  107 BM cells (n Z 5); 33.5% of CD45 cells
showed expression of CD271. This analysis conﬁrmed
CD271þ cell enrichment using the Stemcell Technologies
EasySep Mouse Mesenchymal Stem/Progenitor Cell
Enrichment Kit (catalog number 19771) for mouse MSCs.
All experiments were approved by Tufts University (Graf-
ton, MA) Institutional Biosafety Committee (GRIA04) and
Institutional Animal Care and Use Committee (G2012-151).
Results
Virulent M. tuberculosis Disseminates to the BM within
2 Weeks of Infection
Our initial observation that showed that M. tuberculosis
could infect and reside in vivo in the mouse BM-MSCs was
done using the i.v. route of infection and an avirulent strain
ofM. tuberculosis.5 To conﬁrm those ﬁndings after a natural
route of M. tuberculosis transmission, mice were initially
infected with a low dose (approximately 80 CFUs) of
aerosolized virulent M. tuberculosis (Erdman strain). Mice
were then euthanized at different time points after the
infection, and the BM target cells of the infectious process
were evaluated. After infection, typical bacillary growth for
C57BL/6 mice was observed, peaking at 3 to 4 weeks and
then declining by approximately 10-fold to a stable CFU
burden (Figure 1).13,14 The sharp slowing of the bacterial
growth rate and decline in bacterial burden between days 28
and 42 in the lungs correspond to the timing for the gen-
eration and manifestation of acquired anti-M. tuberculosis
type 1 helper T-cell immunity.1,14 Interestingly, between
days 7 and 14 after aerosol exposure to M. tuberculosis, the
bacteria disseminated from the lungs to the BM (Figure 1).
This dissemination is similar to that observed in spleen (not
shown) and liver.1,15 Thus, it seems that M. tuberculosis
enters the BM before the initiation of acquired immunity.3171
Figure 2 The M. tuberculosis disseminates to bone marrow (BM) during
early and chronic infection and preferentially infects CD271þ cells. A: Mice
were infected with 72 21 virulentM. tuberculosis Erdman bacilli by aerosol.
At the indicated time points, BM cell fractions were obtained after negative
selection for BM-mesenchymal stem cell. Viable M. tuberculosis colony
forming units were recovered from each cell fraction. Data are from four to
ﬁve mice per time point and shown as means  SEM. Results were analyzed
by one-way analysis of variance with Tukey’s post test. B: Representative
ﬂow cytometry panel shows the presence of CD271þ/CD45 cells in the
enriched population for mouse MSCs (blue dots). Isotype controls are indi-
cated in red. ***P < 0.001.
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Figure 1 The M. tuberculosis disseminates, grows, and survives in bone
marrow (BM) during early and chronic infection. Mice were infected with
82  52 virulent M. tuberculosis Erdman bacilli by aerosol. At the indicated
time points, viable M. tuberculosis CFUs were recovered from the lungs (A)
and BM (B). Data are combined from two independent experiments each
with four to six mice per time point (n Z 8 to 12 mice) and shown as
means  SEM.
Beamer et alMoreover, and in contrast to the lungs, spleen, and liver (not
shown in this study), the kinetics of the M. tuberculosis
burden in the BM do not follow the pattern of a striking
peak and decline in these organs, but instead, in the BM, the
bacterial burden increases early and remains stable for at
least 120 days (Figure 1). These results are consistent with
our former observation pointing to BM as a secondary target
organ of the infectious process that follows the lung colo-
nization of virulent aerosolized M. tuberculosis.
Virulent M. tuberculosis that Disseminate from Lung to
BM Preferentially Reside within the MSC Subpopulation
To verify the BM cell target of M. tuberculosis, mice were
challenged with aerosolized bacteria and their BM cells
were subsequently harvested at different time points. These
experiments aimed to conﬁrm that viable M. tuberculosis
preferentially target BM-MSCs. Harvested BM cells were
separated by negative selection (Stemcell Technologies
EasySep Mouse Mesenchymal Stem/Progenitor Cell
Enrichment Kit) into two subpopulations of cells, one that
expresses CD271þCD45 (BM-MSCs) and a second
population of cells that are CD271CD45þ. To verify
which cell population was preferentially infected with
M. tuberculosis, the fractions of BM cells were indepen-
dently inoculated in oleate-albumin-dextrose-cata-
laseeenriched Middlebrook agar plates and incubated at
37C for at least 3 weeks, followed by enumeration of the
bacterial CFUs. Throughout the infection process, the
burden of M. tuberculosis infection (CFU) was 10-fold
higher in the CD271þCD45-enriched BM cell fraction
(BM-MSCs) than in the CD271-depleted cell population
(Figure 2). This preferential BM targeting by
M. tuberculosis occurs as early as 14 days after lung
challenge and is maintained throughout the chronic phase
of the infection. As expected, the CD271þCD45 depleted
cell population also contains a relatively high level of3172infection because this population of cells comprises other
cell types, including macrophages, a well-known popula-
tion of cells that are normally infected by M. tuberculosis.
Moreover, the depletion procedure did not non-speciﬁcally
remove infected CD271 cells because the CFUs recov-
ered from the unfractionated population of cells did not
differ from the CD271þ-depleted cell population
(Figure 2). On the other hand, it is possible that the
depleted CD271þ cells still contain CD271þCD45 cells
because enrichment procedure does not fully deplete the
latter cells. Nonetheless, these results clearly conﬁrm that
virulent M. tuberculosis enters the mammalian host
through the respiratory tract and subsequently infects
MSCs in a remote tissue like the BM.ajp.amjpathol.org - The American Journal of Pathology
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Figure 4 The M. tuberculosis bacilli are preferentially recovered from
CD271þCD45 bone marrow cells after anti-tuberculosis therapy. Mice were
infected with 72  21 M. tuberculosis Erdman bacilli by aerosol. Starting at
day 28 of M. tuberculosis infection, mice received rifampicin and isoniazid
in the drinking water. After 4 weeks of antibiotic therapy, BM was har-
vested, followed by separation of CD271þCD45 and CD271CD45þ cell
fractions by negative selection. Cells were dispersed for M. tuberculosis
culture, and CFU was determined after at least 3 weeks of incubation at
37C. Data are from four to six mice per group and shown as the
means  SEM. Control colony forming unit (CFU) yields for mice receiving
sterile water (instead of antibiotics) are depicted in Figure 2 (experiments
were performed concomitantly).
BM-MSCs Protect M.tb from AntibioticsAntibiotics Are Not as Effective at Treating Virulent
M. tuberculosis in the BM Compared with Lungs and
Spleens
Our initial observation in humans indicated that TB patients
successfully treated and considered cured still harbored
viableM. tuberculosis in their BM-MSCs.5 It is possible that
this biological state of resistance to therapy could be a
consequence of efﬂux pump transporters present in these
cells.5,16,17
To begin to evaluate a role for BM-MSCs as a protective
niche allowing M. tuberculosis to evade therapy by antibi-
otic drugs, we took advantage of a well-established animal
model of dormant TB. In this model, known for >50 years
as the Cornell model,18e20 mice are infected with virulent
M. tuberculosis and the resultant infection is typically
treated for 12 weeks with the anti-mycobacterial drugs,
which eliminates cultivable tubercle bacilli from the lungs,
spleen, and livers. However, the condition can revert
spontaneously or be induced by immune-suppressive drugs,
and M. tuberculosis can again be cultured from lungs and
spleens of approximately 50% of the animals. This indicates
that in some mice, tubercle bacilli were present somewhere
and somehow protected from the antibiotics. Because BM is
a major niche of MSCs, we hypothesized that viable
M. tuberculosis could still be present in BM even after
successful sterilization of the lungs and spleen. In
M. tuberculosis-infected mice, which received continuous
treatment with RIF and INH starting 28 days after infection,
viable M. tuberculosis were still present in BM for at least
100 days after no more viable M. tuberculosis could be
recovered from the lungs and spleens (Figure 3). Interest-
ingly, after the initiation of the antibiotic therapy, there was
a steep and equal reduction of the viable M. tuberculosis
that could be recovered from lungs and spleens, which lead1
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Figure 3 The M. tuberculosis survives in the bone marrow (BM) after
anti-tuberculosis therapy. Mice were infected with 82  52 M. tuberculosis
Erdman bacilli by aerosol. Starting at day 28 of M. tuberculosis infection,
mice received rifampicin and isoniazid continuously in the drinking water.
At the indicated time points, viable M. tuberculosis colony forming unit
(CFU) were recovered from lungs, spleens, and BM. Data are from two in-
dependent experiments each with four to six mice per time point (nZ 8 to
12 mice) and shown as the means  SEM. The last time points that M.
tuberculosis could be recovered from the spleens and lungs were after 65
and 93 days, respectively, of continuous antibiotic therapy (days 121 and
220 after infection, respectively). In contrast, viable M. tuberculosis CFUs
could be recovered from BM at all of the time points tested. Control CFU
yields for mice receiving sterile water (instead of antibiotics) are depicted
in Figure 1 (experiments were performed concomitantly).
The American Journal of Pathology - ajp.amjpathol.orgto undetectable levels of viable M. tuberculosis (CFU). In
contrast, no sterilization occurred in the BM, although there
was a reduction in viable M. tuberculosis that reached the
maximum at day 91 after infection (7 weeks of continuous
antibiotic therapy). From then on, M. tuberculosis bacilli
plateaued at low numbers until the end of the experiment at
day 220 after infection (after >6 months of continuous
antibiotic therapy). The level of detection in our assays was
equivalent for the lungs, spleens, and BM.
To identify the cell population in the BM that hosts and
protects the M. tuberculosis from RIF/INH, mice were
infected for 28 days, followed by treatment with the antibi-
otics for 4 weeks. BM cells were obtained and separated as
described above into CD271þCD45 cells and
CD271CD45þ cells.M. tuberculosis bacilli were 100 times
more numerous in the CD271þCD45 cell population than in
the CD271CD45þ cell fraction (Figure 4). These results
clearly indicate that BM-MSCs constitute a unique cellular
niche, which, in the Cornell model of M. tuberculosis
persistence, protects the bacteria from therapeutic properties
of antibiotics that are used to treat TB.
Discussion
Our previous work established that BM cells, in particular, the
CD271þCD45 BM-MSCs, harbor viable M. tuberculosis
bacilli.5 However, these studies did not address the kinetics of
dissemination from the lungs and persistence of virulent
M. tuberculosis in the BM or explore temporal relationships
between growth of the M. tuberculosis in the BM, compared3173
Beamer et alwith the primary site of infection and disease (lungs) or other
secondary sites (spleen). Understanding these fundamental
processes in vivo is important because the results have
mechanistic implications for M. tuberculosis latent TB infec-
tion, which affects billions of people across the globe.21
Because these experiments cannot be performed in humans,
we used the most common inbred mouse strain in
M. tuberculosis research: C57BL/6 mice. C57BL/6 mice are
well-known to be relatively resistant to low-dose aerosol
infection of virulent M. tuberculosis (as we used herein) with
survival >1 year,22 attributed to strong antimycobacterial
immunity due to numerous and potent antigen-speciﬁc T
cells.13,23 Thus, we used C57BL/6 mice as a model for
studying M. tuberculosis in the BM of hosts capable of
mounting strong type 1 helper T-cellepolarized anti-
M. tuberculosis immunity.
Herein, we deﬁne that, after lung infection of mice with
virulent M. tuberculosis, the infectious process disseminates
not only to organs like spleen and liver but to BM as well.
Interestingly, the pattern of growth and control of the
M. tuberculosis in the lungs, spleen, and liver1,13e15 is not
the same to that occurring with M. tuberculosis in the BM.
In contrast to the lung, spleen, and liver, where growth is
limited and burden declines because of robust immunity, the
growth of the bacteria in the BM does not decline during the
chronic phase of infection. Although we have not yet
formally investigated the biological and molecular mecha-
nisms that contribute to this phenomenon, it is possible that
M. tuberculosis within the BM is protected from the host
immune response because this tissue is generally considered
an immune-privileged niche,10,11 and this is supported by
our observation that no granulomas formed within the BM
(not shown).
More important, the present studies clearly demonstrate
that M. tuberculosis, in addition to the CD45þ cells, also
resides in the BM within the unique MSC population
(CD271þCD45 cells). The results that supported this
conclusion (Figure 2) indicated that proportionally the
CD271þCD45 cells were more infected than the CD45þ
population of cells. However, it is important to keep in mind
that during the in vivo infectious process, the CD45þ cell
population constitutes a major target of the M. tuberculosis
infection because these cells are disparately more numerous
than the CD271þCD45 cell population. Nonetheless,
because of the unique properties of the MSCs, the results
strongly support the proposed hypothesis that infection of
these cells constitutes an important M. tuberculosis escape
mechanism of survival within the host. At this point,
nothing is known about the mechanism of internalization of
M. tuberculosis into the BM-MSCs. It is possible that the
ﬁnal localization of the bacteria within these cells may be a
stepwise process (ie, the M. tuberculosis may be initially
internalized into conventional host cells, like macrophages,
followed by subsequent dedifferentiation into stem cells).
Indeed, this set of events has recently and elegantly been
demonstrated to be the case for Mycobacterium3174lepraeeinfected Schwann cells.24 This report shows that
the leprosy bacterium induces the macrophage-like adult
Schwann cells, the preferred host cells for M. leprae, to
reprogram their differentiation to a stage of progenitor/
stem-like cells by down-regulating cell lineage/
differentiation-associated genes and up-regulating genes
mostly of mesoderm development. Although hypothetical,
this is an attractive mechanism to explain our observations
that M. tuberculosis can be found internalized and likely
persist within BM-MSCs.
The persistence of M. tuberculosis may represent an
important escape mechanism from both the host immune
response and may mask them from the reach of anti-TB
drugs. The evasion of the immune response is likely to
occur within the BM-MSCs because these cells do not
normally express MHC class II on their cell surface and their
MHC class I molecules are not functionally active and do
not trigger effector functions of cytotoxic T lymphocytes.12
Protection from drugs is likely to be achieved because BM-
MSCs have potent efﬂux pump transporters of ABCG2,5 an
ATP-binding cassette family member that can pump a di-
versity of organic molecules, including the anti-TB antibi-
otic RIF, out of the cells.16,17 Indeed, our data lend support
to this hypothesis. By using the well-established Cornell
mouse model to study M. tuberculosis persistence after drug
therapy, for the ﬁrst time, our results clearly showed that
even with prolonged and continuous treatment for >6
months with INH and RIF, the bacterium could still be
recovered from the BM. In contrast and as expected from the
Cornell model, no M. tuberculosis could be isolated from
the lungs or spleen. These results identify a hidden location
of the residual and viable M. tuberculosis present in mice in
the Cornell model, which has been elusive for >50 years.
More important, our results clearly identiﬁed that within the
BM cells of antibiotic-treated mice, the pathogen was iso-
lated primarily from the CD271þCD45 (BM-MSCs). In
contrast, only fewM. tuberculosis could be isolated from the
CD271CD45þ cells (monocytes, macrophages, and other
phagocytic cells). However, because the CD271þCD45
enriched cell population was obtained by negative selec-
tion, other cells besides BM-MSCs may be present in this
BM cell fraction. Therefore, other possible targets of
infection by M. tuberculosis that could also help the
pathogen escape antibiotic treatment cannot be excluded.
However, the fact that the depleted fraction contained few
organisms strongly supports the hypothesis that the
BM-MSCs can protect M. tuberculosis from long-term
administration of RIF/INH. These observations are highly
relevant, because they may explain why it can be
exceedingly difﬁcult to achieve complete microbial steril-
ization of TB patients with antibiotics.
In conclusion, by using a stringent in vivo model of TB,
these results strongly support the proposal that BM-MSCs
are important target cells of the infection process that pro-
vides a robust antibiotic-protective niche for M. tuberculosis
to survive therapy within its host. In addition, these studiesajp.amjpathol.org - The American Journal of Pathology
BM-MSCs Protect M.tb from Antibioticssuggest that unraveling the mechanisms underlying the
M. tuberculosis and BM-MSC interactions will enhance our
understanding of M. tuberculosis persistence under immune
and antibiotic pressures in TB patients.
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